Skip to content

SOCI - Standing Committee

Social Affairs, Science and Technology

Past Session: Past Session:
42-1 42nd Parliament, 1st Session (December 3, 2015 - September 11, 2019)
Select a different session
 

Proceedings of the Standing Senate Committee on
Social Affairs, Science and Technology

Issue No. 24 - Minutes of Proceedings - May 18, 2017 (morning)

OTTAWA, Thursday, May 18, 2017
(54)

[English]

The Standing Senate Committee on Social Affairs, Science and Technology met this day at 10:30 a.m., in room 2, Victoria Building, the chair, the Honourable Kelvin Kenneth Ogilvie, presiding.

Members of the committee present: The Honourable Senators Cormier, Dean, Griffin, MacDonald, McIntyre, Mégie, Neufeld, Ogilvie, Petitclerc and Stewart Olsen (10).

Also present: The official reporters of the Senate.

Pursuant to the order of reference adopted by the Senate on Monday, May 8, 2017, the committee began its examination of the subject matter of those elements contained in Divisions 5, 9, 11, 13, 14 and 16 of Part 4 of Bill C-44, An Act to implement certain provisions of the budget tabled in Parliament on March 22, 2017 and other measures.

WITNESSES:

Canadian Institute for Advanced Research (CIFAR):

Dr. Alan Bernstein, President and Chief Executive Officer.

Innovation, Science and Economic Development Canada:

Alison McDermott, Director General, Science and Innovation Sector, Program Coordination Branch.

Health Canada:

David Lee, Executive Advisor to the Assistant Deputy Minister, Health Products and Food Branch;

Ed Morgan, Director General, Policy, Planning and International Affairs Directorate, Health Products and Food Branch;

Naira Minto-Saaed, Director, Strategic Planning and Accountability Division, Resource Management and Operations Directorate, Health Products and Food Branch;

Deryck Trehearne, Director General, Resource Management and Operations Directorate, Health Products and Food Branch.

Innovative Medicines Canada:

Declan Hamill, Vice-President, Legal, Regulatory and Policy;

Keith McIntosh, Executive Director, Scientific and Regulatory Affairs.

Canadian Generic Pharmaceutical Association:

Jim Keon, President;

Jody Cox, Vice-president, Federal and International Affairs.

The chair made a statement.

Dr. Bernstein made a statement and, together with Ms. McDermott, answered questions.

At 10:59 a.m., the committee suspended.

At 11:03 a.m., the committee resumed.

Mr. Morgan made a statement and, together with Mr. Lee, Ms. Minto-Saaed and Mr. Trehearne, answered questions.

At 11:29 a.m., the committee suspended.

At 11:32 a.m., the committee resumed.

Mr. Hamill and Mr. Keon each made a statement and answered questions.

At 11:51 a.m., the committee suspended.

At 11:53 a.m., the committee resumed in camera.

It was agreed that senators' staff be permitted to remain in the room for the in camera portion of the meeting.

It was agreed to permit the recording and transcription of the in camera portion of the meeting, that one copy of the transcript be kept with the clerk for consultation purposes, and that the copy be destroyed at the end of the current parliamentary session.

Pursuant to rule 12-16(1)(d), the committee discussed a draft report.

It was agreed that the committee recommend the approval of Divisions 5 and 16 of Bill C-44, An Act to implement certain provisions of the budget tabled in Parliament on March 22, 2017 and other measures.

It was agreed that the steering committee approve the final version of the text relating to Divisions 5 and 16 of Bill C-44, taking into account today's discussion.

At 12:07 p.m., the committee adjourned to the call of the chair.

ATTEST:

Shaila Anwar

Clerk of the Committee

Back to top